医学                        
                
                                
                        
                            表皮生长因子受体                        
                
                                
                        
                            肺癌                        
                
                                
                        
                            肿瘤科                        
                
                                
                        
                            双特异性抗体                        
                
                                
                        
                            癌症研究                        
                
                                
                        
                            内科学                        
                
                                
                        
                            抗体                        
                
                                
                        
                            癌症                        
                
                                
                        
                            皮肤病科                        
                
                                
                        
                            免疫学                        
                
                                
                        
                            单克隆抗体                        
                
                        
                    
            作者
            
                Shahnaz Singh-Kandah,Kaiwen Wang,Karen Xia,Andy Lain Johnson,Denise D’Andrea,Catherine A. Shu,Lindsay Dougherty,Stephanie M. Gallitano            
         
                    
        
    
            
            标识
            
                                    DOI:10.1188/24.cjon.1-8.ap
                                    
                                
                                 
         
        
                
            摘要
            
            Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition.
         
            
 
                 
                
                    
                    科研通智能强力驱动
Strongly Powered by AbleSci AI